[1] Milena Ilic and Irena Ilic (2016) “Epidemiology of pancreatic cancer”World J Gastroenterol.
2016 Nov 28; 22(44): 9694–9705.
doi: 10.3748/wjg.v22.i44.9694
[2] A.
Carrato, A.
Falcone, M.
Ducreux, J.
W.
Valle, A.
Parnaby, K.
Djazouli, K.
Alnwick-Allu, A.
Hutchings, C.
Palaska, and I.
Parthenaki (2015) “A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival,
Quality of Life and Costs” J Gastrointest Cancer.
2015doi: 10.1007/s12029-015-9724-1
[3] Inne Somers and Shandra Bipat (2017) Contrast-enhanced CT in determining resectability in patients with pancreatic carcinoma: a meta-analysis of the positive predictive values of CT.
Eur Radiol.
2017; 27(8): 3408–3435.
. doi: 10.1007/s00330-016-4708-5
[4] Callery MP,
Chang KJ,
Fishman EK,
Talamonti MS,
William Traverso L,
Linehan DC (2009) “Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement” Ann Surg Oncol. 2009 Jul;16(7):1727-33.
doi: 10.1245/s10434-009-0408-6.
[5] National Comprehensive Cancer Network I.
Clinical practice guidelines in oncology: pancreatic adenocarcinoma.
Version 2.
2012
[6] Edward P.
Balaban,
Pamela B.
Mangu,
and Nelson S.
Yee (2016) Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.
American Society of Clinical Oncology 2016 DOI: 10.1200/JOP.2016.017376
[7] Darren D.
D.
Brennan,
Giulia A.
Zamboni,
Vassilios D.
Raptopoulos,
Jonathan B.
Kruskal (2007) Comprehensive Preoperative Assessment of Pancreatic Adenocarcinoma with 64-Section Volumetric CT. RadioGraphics 2007; 27:1653–1666 .
Published online 10.1148/rg.276075034
[8] Diego A.S.
Toesca,
Amanda J.
Koong,
George A.
Poultsides,
Brendan C.
Visser,
Sigurdis Haraldsdottir,
Albert C.
Koong,
and Daniel T.
Chang (2018) Management of Borderline Resectable Pancreatic Cancer.
Int J Radiat Oncol Biol Phys. 1;100(5):1155-1174.
doi: 10.1016/j.ijrobp.2017.12.287.